MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roche’s checkpoint inhibitor atezolizumab, for the treatment of multiple hard-to-treat cancers. MAIA Chairman and CEO Vlad Vitoc stated that preclinical studies found ateganosine to be highly synergistic with atezolizumab.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA:
- MAIA Biotechnology Enters Inducement Offer Agreements
- MAIA Biotechnology Reports Positive Phase 2 Trial Results
- MAIA Biotechnology announces new partial response in Phase 2 THIO-101 trial
- MAIA Biotechnology announces updated data from THIO-101 trial
- MAIA Biotechnology Showcases Promising THIO-101 Trial Data